Gastrointestinal Cancers: Timing Is Everything.
作者信息
Apisarnthanarax Smith, Jabbour Salma K, Liauw Stanley L, Murphy James D, Olsen Jeffrey R, Chang Daniel T
出版信息
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1051-1058. doi: 10.1016/j.ijrobp.2017.05.040.
Abstract
摘要
相似文献
1
Gastrointestinal Cancers: Timing Is Everything.胃肠道癌症：时机至关重要。
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1051-1058. doi: 10.1016/j.ijrobp.2017.05.040.
2
CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.在评估接受伊马替尼治疗的胃肠道肿瘤（GIST）患者时，CT扫描并非万能。
Pathol Oncol Res. 2012 Oct;18(4):1095-7. doi: 10.1007/s12253-011-9445-0. Epub 2011 Sep 17.
3
Drainage Percutaneous Endoscopic Gastrostomy for Malignant Bowel Obstruction in Gastrointestinal Cancers: Prognosis and Implications for Timing of Palliative Intervention.经皮内镜下胃造瘘术治疗胃肠道恶性肿瘤所致恶性肠梗阻：预后及对姑息性干预时机的影响
J Palliat Med. 2017 Jul;20(7):774-778. doi: 10.1089/jpm.2016.0465. Epub 2017 Feb 16.
4
THE CHANGING TREND OF MORTALITY CAUSED BY GASTROINTESTINAL CANCERS IN IRAN DURING THE YEARS 2006-2010.2006 - 2010年伊朗胃肠道癌症所致死亡率的变化趋势
Arq Gastroenterol. 2018 Jul-Sep;55(3):237-241. doi: 10.1590/S0004-2803.201800000-60.
5
Second primary cancers in patients with gastrointestinal cancers.胃肠道癌症患者的第二原发性癌症。
Jpn J Clin Oncol. 1985 Apr;15 Suppl 1:171-82.
6
Trends in Mortality Rates for Gastrointestinal Cancers in Fars Province, Iran (2005-2015).伊朗法尔斯省胃肠道癌症死亡率趋势（2005 - 2015年）
J Gastrointest Cancer. 2020 Mar;51(1):63-69. doi: 10.1007/s12029-019-00204-1.
7
Editorial: Chronology of gastrointestinal cancers and gastrointestinal microbiota.社论：胃肠道癌症与胃肠道微生物群的时间顺序
Front Endocrinol (Lausanne). 2023 Apr 13;14:1179413. doi: 10.3389/fendo.2023.1179413. eCollection 2023.
8
Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis.囊性纤维化患者患胃肠道癌症的风险：系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):758-767. doi: 10.1016/S1470-2045(18)30188-8. Epub 2018 Apr 26.
9
Antioxidants and prevention of gastrointestinal cancers.抗氧化剂与胃肠道癌的预防。
Curr Opin Gastroenterol. 2013 Mar;29(2):195-200. doi: 10.1097/MOG.0b013e32835c9d1b.
10
Cytoreductive surgery in advanced GIST: timing is everything.晚期胃肠道间质瘤的细胞减灭术：时机至关重要。
Ann Surg Oncol. 2013 Dec;20(13):4059-60. doi: 10.1245/s10434-013-3281-2. Epub 2013 Oct 1.
本文引用的文献
1
Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR).多中心、随机、III 期临床试验：短期放疗联合化疗与长程放化疗治疗局部进展期直肠癌（STELLAR）。
J Clin Oncol. 2022 May 20;40(15):1681-1692. doi: 10.1200/JCO.21.01667. Epub 2022 Mar 9.
2
Nonoperative Management or 'Watch and Wait' for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal.新辅助放化疗后临床完全缓解的直肠癌的非手术治疗或“观察等待”：一项批判性评估
Ann Surg Oncol. 2017 Jul;24(7):1904-1915. doi: 10.1245/s10434-017-5841-3. Epub 2017 Mar 21.
3
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.肛管鳞状细胞癌放化疗后评估完全临床缓解的最佳时间（ACT II）：一项随机对照3期试验的事后分析
Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11.
4
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.术前放疗的最佳分割和直肠癌手术时机（斯德哥尔摩 III）：一项多中心、随机、非盲、III 期、非劣效性试验。
Lancet Oncol. 2017 Mar;18(3):336-346. doi: 10.1016/S1470-2045(17)30086-4. Epub 2017 Feb 10.
5
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.比较吉西他滨和卡培他滨辅助治疗与吉西他滨单药治疗可切除胰腺癌患者的效果（ESPAC-4）：一项多中心、开放标签、随机、3 期临床试验。
Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.
6
Long-term Survival After Chemoradiotherapy Without Surgery for Rectal Adenocarcinoma: A Word of Caution.直肠癌单纯放化疗而非手术治疗后的长期生存：一则警示
JAMA Oncol. 2017 Jan 1;3(1):123-125. doi: 10.1001/jamaoncol.2016.3424.
7
Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04).术前短程放疗与长程放化疗治疗直肠T3腺癌的随机试验中的急性不良事件和术后并发症：跨塔斯曼放射肿瘤学组试验（TROG 01.04）
Ann Surg. 2017 May;265(5):882-888. doi: 10.1097/SLA.0000000000001987.
8
Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.新辅助治疗后切除与直接切除可切除胰腺癌：倾向评分匹配分析。
J Clin Oncol. 2017 Feb 10;35(5):515-522. doi: 10.1200/JCO.2016.68.5081. Epub 2016 Sep 30.
9
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).新辅助放化疗与手术间隔（7 或 11 周）对直肠癌完全病理缓解的影响：一项多中心、随机、对照试验（GRECCAR-6）。
J Clin Oncol. 2016 Nov 1;34(31):3773-3780. doi: 10.1200/JCO.2016.67.6049.
10
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.术前改良FOLFIRINOX方案治疗后序贯卡培他滨同步放化疗用于可切除边缘的胰腺癌：肿瘤临床试验联盟A021101试验
JAMA Surg. 2016 Aug 17;151(8):e161137. doi: 10.1001/jamasurg.2016.1137.
Zotero 插件